Q3 EPS Estimate for Revolution Medicines Reduced by Analyst

Revolution Medicines, Inc. (NASDAQ:RVMD) – Analysts at Leerink Partnrs decreased their Q3 2025 earnings estimates for shares of Revolution Medicines in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($1.45) per share for the quarter, down from their previous forecast of ($1.07). The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.61) EPS, FY2025 earnings at ($5.50) EPS and FY2026 earnings at ($5.25) EPS.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.37). The company’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.81) EPS.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $72.00 target price (down previously from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Oppenheimer boosted their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. The Goldman Sachs Group assumed coverage on shares of Revolution Medicines in a research report on Tuesday, July 15th. They set a “buy” rating and a $65.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Revolution Medicines in a report on Wednesday, June 25th. Finally, Needham & Company LLC dropped their price objective on shares of Revolution Medicines from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $68.82.

Revolution Medicines Stock Down 0.9%

NASDAQ:RVMD opened at $34.70 on Monday. The company has a market cap of $6.49 billion, a PE ratio of -7.71 and a beta of 1.16. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $62.40. The company has a current ratio of 11.79, a quick ratio of 11.79 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $38.30 and its two-hundred day moving average is $38.69.

Hedge Funds Weigh In On Revolution Medicines

Several large investors have recently made changes to their positions in the company. Farallon Capital Management LLC lifted its stake in shares of Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company’s stock valued at $579,498,000 after purchasing an additional 1,931,000 shares during the period. Wellington Management Group LLP raised its position in Revolution Medicines by 8.9% during the first quarter. Wellington Management Group LLP now owns 11,787,921 shares of the company’s stock worth $416,821,000 after acquiring an additional 966,230 shares during the period. Janus Henderson Group PLC raised its position in Revolution Medicines by 54.5% during the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company’s stock worth $414,777,000 after acquiring an additional 3,346,755 shares during the period. Baker BROS. Advisors LP raised its position in Revolution Medicines by 4.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company’s stock worth $347,163,000 after acquiring an additional 367,882 shares during the period. Finally, Nextech Invest Ltd. raised its position in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.